{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T15:40:18Z","timestamp":1717342818932},"reference-count":77,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","revespcardiol.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.rec.2018.05.015","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:09:46Z","timestamp":1530144586000},"page":"847-855","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction"],"prefix":"10.1016","volume":"71","author":[{"given":"Maria","family":"Mahmood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rec.2018.05.015_bib0390","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000368422","article-title":"Clinical Significance of Chronic Kidney Disease and Atrial Fibrillation on Morbidity and Mortality in Patients with Acute Myocardial Infarction","volume":"40","author":"Hwang","year":"2014","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.rec.2018.05.015_bib0395","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2007111207","article-title":"Dilemmas in the management of atrial fibrillation in chronic kidney disease","volume":"20","author":"Reinecke","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.rec.2018.05.015_bib0400","first-page":"1217","article-title":"Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making","volume":"2017","author":"Lip","year":"2017","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.rec.2018.05.015_bib0405","first-page":"75","article-title":"Methods of estimating GFR\u2013different equations including CKD-EPI","volume":"32","author":"Florkowski","year":"2011","journal-title":"Clin Biochem Rev."},{"key":"10.1016\/j.rec.2018.05.015_bib0410","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int."},{"key":"10.1016\/j.rec.2018.05.015_bib0415","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/ndt\/gfv289","article-title":"Defining end-stage renal disease in clinical trials: a framework for adjudication","volume":"31","author":"Agarwal","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.rec.2018.05.015_bib0420","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4161\/org.7.1.13997","article-title":"Renal replacement therapy review: Past, present and future","volume":"7","author":"Fleming","year":"2011","journal-title":"Organogenesis."},{"key":"10.1016\/j.rec.2018.05.015_bib0425","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2010.12.013","article-title":"Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation: Implications for Thromboprophylaxis and Bleeding Risk","volume":"57","author":"Marinigh","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2018.05.015_bib0430","doi-asserted-by":"crossref","unstructured":"Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). Am Heart J.159:1102-1107.","DOI":"10.1016\/j.ahj.2010.03.027"},{"key":"10.1016\/j.rec.2018.05.015_bib0435","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2215\/CJN.10921015","article-title":"Atrial Fibrillation and Risk of ESRD in Adults with CKD","volume":"11","author":"Bansal","year":"2016","journal-title":"Clinical J Am Soc Nephrol."},{"key":"10.1016\/j.rec.2018.05.015_bib0440","doi-asserted-by":"crossref","first-page":"e002097","DOI":"10.1161\/JAHA.112.002097","article-title":"Impact of chronic kidney disease on risk of incident atrial fibrillation and subsequent survival in medicare patients","volume":"1","author":"Nelson","year":"2012","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.rec.2018.05.015_bib0445","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest."},{"key":"10.1016\/j.rec.2018.05.015_bib0450","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.hrthm.2014.06.021","article-title":"Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis","volume":"11","author":"Chao","year":"2014","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.rec.2018.05.015_bib0455","doi-asserted-by":"crossref","first-page":"e000250","DOI":"10.1161\/JAHA.113.000250","article-title":"A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score","volume":"2","author":"Singer","year":"2013","journal-title":"J Am Heart Assoc."},{"key":"10.1016\/j.rec.2018.05.015_bib0460","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.112.107128","article-title":"Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF and ATRIA study cohorts","volume":"127","author":"Piccini","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2018.05.015_bib0465","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/eurheartj\/ehu139","article-title":"Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study","volume":"36","author":"Friberg","year":"2014","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2018.05.015_bib0470","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1093\/eurheartj\/eht328","article-title":"Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial","volume":"34","author":"Apostolakis","year":"2013","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2018.05.015_bib0475","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1160\/TH13-01-0054","article-title":"Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?","volume":"110","author":"Rold\u00e1n","year":"2013","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.rec.2018.05.015_bib0480","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest."},{"key":"10.1016\/j.rec.2018.05.015_bib0485","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/jth.13386","article-title":"Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores","volume":"14","author":"Lip","year":"2016","journal-title":"Journal of Thromb Haemost."},{"key":"10.1016\/j.rec.2018.05.015_bib0490","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.amjmed.2017.09.009","article-title":"Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation","volume":"131","author":"Guo","year":"2018","journal-title":"Am J Med."},{"key":"10.1016\/j.rec.2018.05.015_bib0495","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1160\/TH17-10-0710","article-title":"Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED Score. The AMADEUS Trial","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.rec.2018.05.015_bib0500","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/emermed-2015-204891","article-title":"Coagulation assessment with the new generation of oral anticoagulants","volume":"33","author":"Pollack","year":"2016","journal-title":"Emerg Med J."},{"key":"10.1016\/j.rec.2018.05.015_bib0505","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1681\/ASN.2008070802","article-title":"Kidney function influences warfarin responsiveness and hemorrhagic complications","volume":"20","author":"Limdi","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.rec.2018.05.015_bib0510","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfu080","article-title":"Anticoagulation in chronic kidney disease patients\u2014the practical aspects","volume":"7","author":"Hughes","year":"2014","journal-title":"Clin Kidney J."},{"key":"10.1016\/j.rec.2018.05.015_bib0515","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ki.2011.44","article-title":"Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate","volume":"80","author":"Brodsky","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.rec.2018.05.015_bib0520","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1160\/TH17-08-0555","article-title":"Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry","volume":"117","author":"Mazurek","year":"2017","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.rec.2018.05.015_bib0525","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2147\/TCRM.S84210","article-title":"New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events","volume":"11","author":"Mekaj","year":"2015","journal-title":"Therapeutics and clinical risk management."},{"key":"10.1016\/j.rec.2018.05.015_bib0530","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1160\/TH16-10-0757","article-title":"Adherence to oral anticoagulant therapy in patients with atrial fibrillation","volume":"117","author":"Raparelli","year":"2017","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.rec.2018.05.015_bib0535","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF","volume":"67","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2018.05.015_bib0540","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace."},{"key":"10.1016\/j.rec.2018.05.015_bib0545","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.amjcard.2017.09.030","article-title":"Non\u2013Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease","volume":"121","author":"Nishimura","year":"2018","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.rec.2018.05.015_bib0550","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11239-013-0956-2","article-title":"Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation","volume":"36","author":"Pokorney","year":"2013","journal-title":"J Thromb Thrombolysis."},{"key":"10.1016\/j.rec.2018.05.015_bib0555","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/ndt\/gft209","article-title":"Haemostasis in chronic kidney disease","volume":"29","author":"Lutz","year":"2013","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.rec.2018.05.015_bib0560","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/IJNRD.S105771","article-title":"Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations","volume":"10","author":"Lutz","year":"2017","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"10.1016\/j.rec.2018.05.015_bib0565","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1681\/ASN.2013040361","article-title":"Comparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKD","volume":"25","author":"Harel","year":"2014","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.rec.2018.05.015_bib0570","first-page":"2137","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"38","author":"Heidbuchel","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2018.05.015_bib0575","article-title":"Novel oral anticoagulants in patients with chronic kidney disease and atrial fibrillation","author":"Stamellou","year":"2017","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.rec.2018.05.015_bib0580","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2018.05.015_bib0585","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2018.05.015_bib0590","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2018.05.015_bib0595","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rec.2018.05.015_bib0600","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2018.05.015_bib0605","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jamacardio.2016.1170","article-title":"Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: Insights from the ARISTOTLE randomized clinical trial","volume":"1","author":"Hijazi","year":"2016","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.rec.2018.05.015_bib0610","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2018.05.015_bib0615","first-page":"2393","article-title":"Effectiveness and Safety of Rivaroxaban Vs. Warfarin in Patients with Nonvalvular Atrial Fibrillation and Moderate-to-Severe Chronic Kidney Disease","volume":"130","author":"Coleman","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.rec.2018.05.015_bib0620","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.rec.2018.05.015_bib0625","first-page":"2137","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"38","author":"Heidbuchel","year":"2017","journal-title":"Eur Heart J."},{"key":"10.1016\/j.rec.2018.05.015_bib0630","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 TrialClinical Perspective","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2018.05.015_bib0635","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1253\/circj.CJ-14-0942","article-title":"Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment","volume":"79","author":"Koretsune","year":"2015","journal-title":"Circulation J."},{"key":"10.1016\/j.rec.2018.05.015_bib0640","first-page":"925","article-title":"Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation","volume":"108","author":"Salazar","year":"2012","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.rec.2018.05.015_bib0645","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.113.003628","article-title":"Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY trial analysis","volume":"129","author":"Hijazi","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2018.05.015_bib0650","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet."},{"key":"10.1016\/j.rec.2018.05.015_bib0655","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijcard.2016.11.303","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: A systematic review and network meta-analysis","volume":"231","author":"And\u00f2","year":"2017","journal-title":"Int J Cardiol."},{"key":"10.1016\/j.rec.2018.05.015_bib0660","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/ndt\/gfu334","article-title":"Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation","volume":"30","author":"Genovesi","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.rec.2018.05.015_bib0665","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1160\/TH13-07-0556","article-title":"Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation","volume":"110","author":"Gallego","year":"2013","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.rec.2018.05.015_bib0670","doi-asserted-by":"crossref","first-page":"e2233","DOI":"10.1097\/MD.0000000000002233","article-title":"Effectiveness and safety of warfarin in dialysis patients with atrial fibrillation: a meta-analysis of observational studies","volume":"94","author":"Liu","year":"2015","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.rec.2018.05.015_bib0675","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/j.ajkd.2007.06.017","article-title":"Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates","volume":"50","author":"Elliott","year":"2007","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.rec.2018.05.015_bib0680","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.cjca.2017.02.010","article-title":"Atrial Fibrillation and End Stage Renal Failure in Patients Receiving Dialysis: Balancing the Risks and Benefits of Stroke Prevention","volume":"33","author":"Voukalis","year":"2017","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.rec.2018.05.015_bib0685","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cjca.2017.02.004","article-title":"Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis","volume":"33","author":"Harel","year":"2017","journal-title":"Can J Cardiol."},{"key":"10.1016\/j.rec.2018.05.015_bib0690","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"Bonde","year":"2014","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2018.05.015_bib0695","first-page":"A17197","article-title":"Contemporary Trends in the Use of Direct Oral Anticoagulants in Dialysis Patients With Atrial Fibrillation in the United States [abstract]","volume":"136","author":"Siontis","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2018.05.015_bib0700","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation."},{"key":"10.1016\/j.rec.2018.05.015_bib0705","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.628","article-title":"Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end stage renal disease on hemodialysis","volume":"56","author":"Wang","year":"2016","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.rec.2018.05.015_bib0710","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.rec.2018.05.015_bib0715","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/phar.1905","article-title":"Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment","volume":"37","author":"Stanton","year":"2017","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.rec.2018.05.015_bib0720","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1002\/phar.1836","article-title":"Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis","volume":"36","author":"Kufel","year":"2016","journal-title":"Pharmacotherapy."},{"issue":"11 Suppl","key":"10.1016\/j.rec.2018.05.015_bib0725","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0735-1097(17)33826-3","article-title":"Evaluation of apixaban in patients on dialysis [abstract]","volume":"69","author":"Dau","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"10.1016\/j.rec.2018.05.015_bib0730","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000445329","article-title":"Rivaroxaban in chronic hemodialysis patients","volume":"43","author":"Muster","year":"2016","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.rec.2018.05.015_bib0735","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000445328","article-title":"Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis","volume":"43","author":"Dias","year":"2016","journal-title":"Am J Nephrol."},{"key":"10.1016\/j.rec.2018.05.015_bib0740","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.ajkd.2015.01.022","article-title":"Dose-finding study of rivaroxaban in hemodialysis patients","volume":"66","author":"De Vriese","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.rec.2018.05.015_bib0745","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1160\/TH14-06-0547","article-title":"Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis","volume":"113","author":"Parasrampuria","year":"2015","journal-title":"Thromb Haemost."},{"key":"10.1016\/j.rec.2018.05.015_bib0750","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis","volume":"61","author":"Chang","year":"2013","journal-title":"Am J Kidney Dis."},{"issue":"Suppl 5","key":"10.1016\/j.rec.2018.05.015_bib0755","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1136\/heartjnl-2017-311726.45","article-title":"46 Audit of new oral anticoagulant monitoring in primary care; are patients being prescribed the correct dose?","volume":"103","author":"Ghai","year":"2017","journal-title":"Heart."},{"key":"10.1016\/j.rec.2018.05.015_bib0760","doi-asserted-by":"crossref","DOI":"10.1111\/eci.12907","article-title":"Kidney Function Monitoring and Non-vitamin K Oral Anticoagulant Dosage in Atrial Fibrillation","author":"Andreu Cayuelas","year":"2018","journal-title":"Eur J Clin Invest."},{"key":"10.1016\/j.rec.2018.05.015_bib0765","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.recesp.2015.06.022","article-title":"Impact of variations in kidney function on nonvitamin K oral anticoagulant dosing in patients with atrial fibrillation and recent acute heart failure","volume":"69","author":"Andreu-Cayuelas","year":"2016","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.rec.2018.05.015_bib0770","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation."}],"container-title":["Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585718302032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1885585718302032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T15:23:09Z","timestamp":1717341789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585718302032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1885585718302032"],"URL":"https:\/\/doi.org\/10.1016\/j.rec.2018.05.015","relation":{},"ISSN":["1885-5857"],"issn-type":[{"value":"1885-5857","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rec.2018.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Cardiolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}